Stock REPL REPLIMUNE GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Replimune Group, Inc.

Equities

REPL

US76029N1063

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
6.97 USD -3.33% Intraday chart for Replimune Group, Inc. -3.06% -17.32%
Apr. 08 Replimune Group Provides Interim Results for Skin Cancer Therapy MT
Mar. 26 Replimune Group, Inc. Announces Management Changes CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Replimune Group Provides Interim Results for Skin Cancer Therapy
MT
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
AQ
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Replimune : Uveal Melanoma Biomarker Poster at AACR 2024
PU
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
AQ
Replimune Group, Inc. Announces Management Changes
CI
Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024
CI
Transcript : Replimune Group, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 10:45 AM
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
AQ
Replimune to Present at Three Upcoming Investor Conferences
AQ
Wedbush Raises Replimune Group's PT to $16 From $14 After Adjusting Financing Assumptions, Keeps Outperform Rating
MT
Replimune Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
AQ
Transcript : Replimune Group, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 11:15 AM
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Wedbush Cuts Replimune Group's PT to $14 From $52 After Narrow Complete Response Rate Miss in Phase 2 Trial of Skin Cancer Treatment Candidate; Keeps Outperform Rating
MT
Barclays Lowers Price Target on Replimune Group to $13 From $50, Keeps Overweight Rating
MT
Sector Update: Health Care Stocks Ease Late Afternoon
MT
Sector Update: Health Care
MT
Replimune Group Shares Slide as Trial of Skin Cancer Treatment Candidate Failed to Meet Primary Endpoints
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. REPL Stock
  4. News Replimune Group, Inc.